The soluble EP2 receptor FuEP2/Ex2 suppresses endometrial cancer cell growth in an orthotopic xenograft model in nude mice

Cancer Letters

Volumn 306, Issue 1, 2011, Pages 67-75

  Takahashi, Tetsuyuki ^a   Ogawa, Hirohisa ^a   Izumi, Keisuke ^a   Uehara, Hisanori ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Decoy receptor; Endometrial cancer; EP2 receptor; Prostaglandin E2

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLOOXYGENASE 2; E PROSTANOID RECEPTOR 1; E PROSTANOID RECEPTOR 2; E PROSTANOID RECEPTOR 3; E PROSTANOID RECEPTOR 4; F PROSTANOID RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROTEIN C FOS; SOLUBLE FRAGMENT OF HUMAN PROSTAGLANDIN E RECEPTOR THAT CONTAINS SECOND EXTRACELLULAR LOOP PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CULTURE MEDIUM; DRUG EFFICACY; ENDOMETRIUM CANCER; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; GROWTH RATE; GROWTH STIMULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSPLANTATION; CULTURE MEDIA; CYCLOOXYGENASE 2; DINOPROSTONE; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE;

MUS; MUS MUSCULUS;

EID: 79955478443     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.02.033     Document Type: Article

References (46)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., Feuer E.J., Thun M.J. Cancer statistics, 2004, CA. J. Cancer J. Clin. 2004, 54:8-29.
2. Ejskjaer K., Sørensen B.S., Poulsen S.S., Forman A., Nexø E., Mogensen O. Expression of the epidermal growth factor system in endometrioid endometrial cancer. Gynecol. Oncol. 2007, 104:158-167.
3. Reynolds R.K., Hu C., Baker V.V. Transforming growth factor-alpha and insulin-like growth factor-I, but not epidermal growth factor, elicit autocrine stimulation of mitogenesis in endometrial cancer cell lines. Gynecol. Oncol. 1998, 70:202-209.
4. Gold L.I., Saxena B., Mittal K.R., Marmor M., Goswami S., Nactigal L., Korc M., Demopoulos R.I. Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res. 1994, 54:2347-2358.
5. Piestrzeniewicz-Ulanska D., Brys M., Semczuk A., Rechberger T., Jakowicki J.A., Krajewska W.M. TGF-beta signaling is disrupted in endometrioid-type endometrial carcinomas. Gynecol. Oncol. 2004, 95:173-180.
6. Ayabe T., Tsutsumi O., Sakai H., Yoshikawa H., Yano T., Kurimoto F., Taketani Y. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr. J. 1997, 44:419-424.
7. Khandwala H.M., McCutcheon I.E., Flyvbjerg A., Friend K.E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 2000, 21:215-244.
8. Oh J.C., Wu W., Tortolero-Luna G., Broaddus R., Gershenson D.M., Burke T.W., Schmandt R., Lu K.H. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol. Biomar. Prev. 2004, 13:748-752.
9. Coleman R.A., Smith W.L., Narumiya S. International union pharmacology classification of prostanoid receptors: properties distribution and structure of the receptors and their subtypes. Pharmacol. Rev. 1994, 46:205-229.
10. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann. Clin. Lab. Sci. 2000, 30:3-21.
11. Jabbour H.N., Milne S.A., Williams A.R., Anderson R.A., Boddy S.C. Expression of COX-2 and PGE synthase and synthesis of PGE2 in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Brit. J. Cancer 2001, 85:1023-1031.
12. Nasir A., Boulware D., Kaiser H.E., Lancaster J.M., Coppola D., Smith P.V., Hakam A., Siegel S.E., Bodey B. Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy. In Vivo 2007, 21:35-43.
13. Yoshimatsu K., Altorki N.K., Golijanin D., Zhang F., Jakobsson P.J., Dannenberg A.J., Subbaramaiah K. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin. Cancer Res. 2001, 7:2669-2674.
14. Jain S., Chakraborty G., Raja R., Kale S., Kundu G.C. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res. 2008, 68:7750-7759.
15. Chen Q., Shinohara N., Abe T., Watanabe T., Nonomura K., Koyanagi T. Significance of COX-2 expression in human renal cell carcinoma cell lines. Int. J. Cancer 2004, 108:825-832.
16. Uefuji K., Ichikura T., Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin. Cancer Res. 2000, 6:135-138.
17. Rask K., Zhu Y., Wang W., Hedin L., Sundfeldt K. Ovarian epithelial cancer: a role for PGE2-synthesis and signaling in malignant transformation and progression. Mol. Cancer 2006, 5:62.
18. Wu T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat. Rev. 2006, 32:28-44.
19. Wang D., Dubois R.N. Cyclooxygenase-2: a potential target in breast cancer. Semin. Oncol. 2004, 31:64-73.
20. Watanabe K., Kawamori T., Nakatsugi S., Ohta T., Ohuchida S., Yamamoto H., Maruyama T., Kondo K., Ushikubi F., Narumiya S., Sugimura T., Wakabayashi K. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 1999, 59:5093-5096.
21. Sonoshita M., Takaku K., Sasaki N., Sugimoto Y., Ushikubi F., Narumiya S., Ohshima M., Taketo M.M. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in APCΔ716 knockout mice. Nat. Med. 2001, 7:1048-1051.
22. Mutoh M., Watanabe K., Kitamura T., Shoji Y., Takahashi M., Kawamori T., Tani K., Kobayashi M., Maruyama T., Kobayashi K., Ohuchida S., Sugimoto Y., Narumiya S., Sugimura T., Wakabayashi K. Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res. 2002, 62:28-32.
23. Takahashi T., Uehara H., Bando Y., Izumi K. Soluble EP2 neutralize prostaglandin E2-induced cell signaling and inhibits osteolytic tumor growth. Mol. Cancer Ther. 2008, 7:2807-2816.
24. Sarkar F.H., Adsule S., Li Y., Padhye S. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev. Med. Chem. 2007, 7:599-608.
25. Cuzick J., Otto F., Baron J.A., Brown P.H., Burn J., Greenwald P., Jankowski J., La Vecchia C., Meyskens F., Senn H.J., Thun M. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009, 10:501-507.
26. Ghosh N., Chaki R., Mandal V., Mandal S.C. COX-2 as a target for cancer chemotherapy. Pharmacol. Rep. 2010, 62:233-244.
27. Kawamori T., Uchiya N., Nakatsugi S., Watanabe K., Ohuchida S., Yamamoto H., Maruyama T., Kondo K., Sugimura T., Wakabayashi K. Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP (1) antagonist, on breast cancer development. Carcinogenesis 2001, 22:2001-2004.
28. Kitamura T., Itoh M., Noda T., Tani K., Kobayashi M., Maruyama T., Kobayashi K., Ohuchida S., Sugimura T., Wakabayashi K. Combined effects of prostaglandin E receptor subtype EP1 and subtype EP4 antagonists on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Cancer Sci. 2003, 94:618-621.
29. Kundu N., Ma X., Holt D., Goloubeva O., Ostrand-Rosenberg S., Fulton AM A.M. Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res. Treat. 2009, 117:235-242.
30. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzascos J.M., Evans J.F., Taketo M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87:803-809.
31. Stillman B.A., Audoly L., Breyer R.M. A conserved threonine in the second extracellular loop of the EP2 and EP4 receptors is required for ligand binding. Eur. J. Pharmacol. 1998, 357:73-82.
32. Audoly L., Breyer R.M. Substitution of charged amino acid residues in transmembrane regions 6 and 7 affect ligand binding and signal transduction of the prostaglandin EP3 receptor. Mol. Pharmacol. 1997, 51:61-68.
33. Sales K.J., Battersby S., Williams A.R., Anderson R.A., Jabbour H.N. Prostaglandin E2 mediates phosphorylation and down-regulation of the tuberous sclerosis-2 tumor suppressor (tuberin) in human endometrial adenocarcinoma cells via the Akt signaling pathway. J. Clin. Endocrinol. Metab. 2004, 89:6112-6118.
34. Milne S.A., Jabbour H.N. Prostaglandin (PG) F (2alpha) receptor expression and signaling in human endometrium: le of PGF (2alpha) in epithelial cell proliferation. J. Clin. Endocrinol. Metab. 2003, 88:1825-1832.
35. Gong Y., Murphy L.C., Murphy L.J. Hormonal regulation of proliferation and transforming growth factors gene expression in human endometrial adenocarcinoma xenografts. J. Steroid Biochem. Mol. Biol. 1994, 50:13-19.
36. Sales K.J., Grant V., Jabbour H.N. Prostaglandin E2 and F2alpha activate the FP receptor and up-regulate cyclooxygenase-2 expression via the cyclic AMP response element. Mol. Cell Endocrinol. 2008, 285:51-61.
37. Wang X., Klein R.D. Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated camp pathway. Mol. Carcinogen. 2007, 46:912-923.
38. Shao J., Jung C., Liu C., Sheng H. Prostaglandin E2 stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer. J. Biol. Chem. 2005, 280:26565-26572.
39. Chen Y., Hughes-Fulford M. Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. Brit. J. Cancer 2000, 82:2000-2006.
40. Tong B.J., Tan J., Tajeda L., Das S.K., Chapman J.A., DuBois R.N., Dey S.K. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia 2000, 2:483-490.
41. Ferrandina G., Legge F., Ranelletti F.O., Zannoni G.F., Maggiano N., Evangelisti A., Mancuso S., Scambia G., Lauriola L. Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer 2002, 95:801-807.
42. Jabbour H.N., Sales K.J., Boddy S.C., Anderson R.A., Williams A.R. A positive feedback loop that regulates cyclooxygenase-2 expression and prostaglandin F2alpha synthesis via the F-series-prostanoid receptor and extracellular signal-regulated kinase 1/2 signaling pathway. Endocrinology 2005, 146:4657-4664.
43. Hasegawa K., Ohashi Y., Ishikawa K., Yasue A., Kato R., Achiwa Y., Nishio E., Udagawa Y. Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor. Int. J. Oncol. 2005, 26:1419-1428.
44. Gao J., Niwa K., Takemura M., Sun W., Onogi K., Wu Y., Seishima M., Mori H., Tamaya T. Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126. Int. J. Oncol. 2005, 26:737-744.
45. Cassano G., Gasparre G., Susca F., Lippe C., Guanti G. Effect of prostaglandin E(2) on the proliferation, Ca(2+) mobilization and camp in HT-29 human colon adenocarcinoma cells. Cancer Lett. 2000, 152:217-222.
46. Sheng H., Shao J., Morrow J.D., Beauchamp R.D., Dubois R.N. Modulation of apoptosis and bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998, 58:362-366.